Theophylline Treatment for Pseudohypoparathyroidism

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
Pseudohypoparathyroidism is a genetic disorder with limited treatment options. Patients have early-onset obesity, short stature and increased risk of type 2 diabetes. This phase 2 clinical trial will test the efficacy of theophylline, a phosphodiesterase inhibitor, in pseudohypoparathyroidism. The investigators hypothesize that theophylline will cause weight loss, improve glucose tolerance and slow growth plate closure in children and young adults.
Epistemonikos ID: a1354064e3651ba4854634cda2edfead1834e076
First added on: May 20, 2024